7 results
Objectives:Primary:- To evaluate efficacy as measured by overall survival (OS), with a goal of demonstrating the superiority of inotuzumab ozogamicin when administered in combination with rituximab, compared with an active comparator arm.Secondary…
- The primary objective of the Stratum 1A cohort is to establish the maximum tolerated dose of single agent InO when administered in children with CD22-positive relapsed/refractory BCPALL.- The primary objective of the phase 2 cohort is to establish…
To validate the use of single urethral sensor catheter in demonstrating urethral pressure variations during filling cystometryIncidence of significant urethral pressure variations during urodynamic filling phase measured with three urethral sensor…
Primary Objectives Efficacy: To demonstrate the superiority of InO monotherapy vs ALLR3 induction in paediatric participants between 1 and < 18 years with HR first bone marrow relapse CD22-positive BCP ALL Secondary Objectives:Key Secondary…
To prospectively test for superiority of atogepant 60 mg QD versus placebo for the prevention of migraine in participants with episodic migraine who have previously failed 2 to 4 classes of oral medications for the prophylaxis of migraine
To evaluate the safety and tolerability of treatment with atogepant 60 mg once daily when administered over 156 weeks for the prevention of migraine in participants with Chronic Migraine (CM) or Episodic Migraine (EM).
The primary objective of ALLTogether is to improve survival and quality of survival in children and young adults with acute lymphoblastic leukaemia